CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS

Treatment as Prevention and Pre-Exposure Prophylaxis

June 11-12, 2012 Royal Garden Hotel, London Sponsored by:



In partnership with: British HIV Association BHIVA

Implementing TasP – Addressing Clinical and Other Concerns Health Workforce Issues Robert Carroll, PhD(c), RN, ACRN



Key Questions to Answer

- How will TasP affect the *clinical census* of patients in care, both current and projected?
 - Overload of healthcare delivery capacity, in human and structural (support) mechanisms
- Is there an *interdisciplinary* approach to care?
 - Alternative Care Models
 - Nurse-led clinics
 - Mental Health & Substance Abuse Treatment
 - Policy-setting
- Are all team members functioning to the full extent of their licensure?
 - Institutional and governmental barriers to practice

CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Treatment as Prevention and Pre-Exposure Prophylaxis

Key Questions to Answer

- How will staff be *trained and educated?*
 - Training and education programs, and health sciences academics
 - Pharmacology
 - Current Adherence Science
 - Clinical Monitoring
- Should staff be *certified* as HIV experts?
 - How will continuing education requirements be addressed & funded?
- How will <u>health literacy</u> be addressed?
- How will patient *coercion* be avoided?

CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Treatment as Prevention and Pre-Exposure Prophylaxis

Contact Information

Robert T. Carroll, PhD(c), RN, ACRN President,

Association of Nurses in AIDS Care

Interactive Communications Project Director, NIDA E-Tools for Prescription Drug Abuse Education IQ Solutions, Rockville, MD

> Email: robcarroll63@me.com Voice: 001-206-351-7525

CONTROLLING THE HIV EPIDEMIC WITH ANTIRETROVIRALS Treatment as Prevention and Pre-Exposure Prophylaxis